Piramal Enterprises is currently trading at Rs 573.90, up by 3.20 points or 0.56% from its previous closing of Rs 570.70 on the BSE.
The scrip opened at Rs 569.00 and has touched a high and low of Rs 573.90 and Rs 565.00 respectively. So far 86 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 624.90 on 28-Mar-2013 and a 52 week low of Rs 395.00 on 06-Nov-2012.
Last one week high and low of the scrip stood at Rs 582.00 and Rs 520.00 respectively. The current market cap of the company is Rs 14729.49 crore.
The promoters holding in the company stood at 53.00% while Institutions and Non-Institutions held 30.03% and 16.97% respectively.
Piramal Enterprises (PEL) has received an approval from the USFDA for its Investigational New Drug (IND) P7435. This is a novel, potent and highly selective, oral diacylglycerol acyltransferase 1 (DGAT1) inhibitor. P7435 has been developed by the NCE Research Division of the company for the management of metabolic disorders such as lipid abnormalities and diabetes.
P7435 has demonstrated its lipid lowering potential in various preclinical studies by showing significant reduction in triglyceride levels, glucose and insulin levels, and decrease in food intake and body weight gain - factors which are associated with lipid abnormalities and metabolic disorders.
The company has established the safety and tolerability of P7435 in a Phase I trial recently completed in India. This extension trial in the US will further evaluate the safety and efficacy of P7435 in a larger population.
Piramal Enterprises is one of India’s largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors.
Company Name | CMP |
---|---|
Bajaj Finance | 6866.25 |
Shriram Finance | 2882.85 |
Aditya Birla Capital | 186.40 |
SBI Cards AndPayment | 691.35 |
Mah & Mah Finl. Serv | 265.00 |
View more.. |